SciELO - Scientific Electronic Library Online

 
vol.20 número2BIRADS 3: CORRELACION HISTOPATOLOGICA DE BAJO POTENCIAL DE MALIGNIDAD, CON CONGLOMERADOS QUISTICOS IMAGENOLOGICOS EN PACIENTES DE TEGUCIGALPACOLESTASIS INTRAHEPATICA EN EL SEGUNDO TRIMESTRE DEL EMBARAZO. REPORTE DE CASO índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista Científica Ciencia Médica

versión impresa ISSN 2077-3323

Resumen

LOPEZ BASCOPE, Eonice et al. METFORMIN IN THE POLYCYSTIC OVARIAN SYNDROME TREATMENT. A RANDOMIZED CLINICAL TRIAL. Rev Cient Cienc Méd [online]. 2017, vol.20, n.2, pp.45-52. ISSN 2077-3323.

Background: Polycystic ovary syndrome is the most frequent cause of anovulatory infertility, characterized by menstrual irregularities, signs of androgen excess, obesityand insulin resistance. Objective: To evaluate the inclusion of sensitizers as metformin, in the treatment of Polycystic ovary syndrome, combined with combined oral contraceptives, versus monotherapy with combined oral contraceptives Materials and methods: A randomized clinical trial was conducted with 60 women aged ≥18 years, divided into 2 homogeneous groups of 30 patients: one received monotherapy with combined oral contraceptives and another received combined treatment of the contraceptives with Metformin. The treatment was performed during 3 cycles of 3 months each. The therapeutic equivalence was compared using the Student's T test for independent samples. Bivariate logistic regression and multimonial logistic regression were used to obtain crude and adjusted Odds Ratio. Results: Average time of remission of the clinic sintoms was lower in the combined therapy, with 3,07 ± 0,21 months for Oligomenorrhea, 3,07 ± 0,21 months for acne, and 7,52 ± 0,42 months for hirsutism; the difference between the means of clinical remission was statistically significant for oligomenorrhea (p = 0,02) and acne (p = 0,001). The mean time of remission by ultrasound was lower in the group receiving combination therapy (6,7 ± 0,23 months), this difference being statistically significant (p = <0,001). Conclusion: Combined treatment of Polycystic ovary syndrome with combined oral contraceptives + Metformin (500mg/day), favors a shorter ultrasound remission, as well as the associated symptoms, and a lower rate of recurrence at 3 months.

Palabras clave : Randomized Controlled Trial; Polycystic Ovary Syndrome; Metformin.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons